Keystone Financial Planning buys $5,811,631 stake in Pfizer (PFE)

Pfizer (PFE) : Keystone Financial Planning scooped up 2,449 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 12, 2016. The investment management firm now holds a total of 175,419 shares of Pfizer which is valued at $5,811,631.Pfizer makes up approximately 3.89% of Keystone Financial Planning’s portfolio.

Other Hedge Funds, Including , Grassi Investment Management reduced its stake in PFE by selling 2,973 shares or 1.21% in the most recent quarter. The Hedge Fund company now holds 243,646 shares of PFE which is valued at $8,071,992. Pfizer makes up approx 1.56% of Grassi Investment Management’s portfolio.Hills Bank Trust Co boosted its stake in PFE in the latest quarter, The investment management firm added 1,070 additional shares and now holds a total of 21,435 shares of Pfizer which is valued at $720,430. Pfizer makes up approx 0.26% of Hills Bank Trust Co’s portfolio.Gradient Investments boosted its stake in PFE in the latest quarter, The investment management firm added 9,975 additional shares and now holds a total of 139,576 shares of Pfizer which is valued at $4,691,149. Pfizer makes up approx 0.46% of Gradient Investments’s portfolio.Chevy Chase Trust Holdings reduced its stake in PFE by selling 100,098 shares or 1.82% in the most recent quarter. The Hedge Fund company now holds 5,390,449 shares of PFE which is valued at $182,736,221. Pfizer makes up approx 1.00% of Chevy Chase Trust Holdings’s portfolio.Washington Trust Bank boosted its stake in PFE in the latest quarter, The investment management firm added 4,292 additional shares and now holds a total of 50,891 shares of Pfizer which is valued at $1,725,205. Pfizer makes up approx 0.41% of Washington Trust Bank’s portfolio.

Pfizer closed down -0.48 points or -1.43% at $33.13 with 1,73,32,125 shares getting traded on Tuesday. Post opening the session at $33.56, the shares hit an intraday low of $32.94 and an intraday high of $33.57 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Investors should note that on Sep 22, 2016, Pfizer announced a cash dividend of $0.3000. The company’s management has announced Nov 9, 2016 as the ex-dividend date and fixed the record date on Nov 11, 2016. The payable date has been fixed on Dec 1, 2016.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Leave a Reply

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.